Medicare Obesity Drug Coverage Starts July 1: What Seniors Need to Know
A landmark Medicare coverage shift for obesity drugs kicks in July 1, but many seniors remain unaware due to limited outreach from government and drugmakers.
If you're on Medicare and struggling with obesity, July 1 is a date you need to circle on your calendar. Starting that day, Medicare will cover obesity medications — a landmark shift that could put blockbuster GLP-1 drugs like those from Eli Lilly and Novo Nordisk within reach for millions of seniors who previously had to pay out of pocket.
Here's the problem: almost nobody knows about it. Neither the government nor the major drug manufacturers — Eli Lilly and Novo Nordisk — have run significant advertising campaigns to spread the word. That means a huge chunk of the seniors who stand to benefit are likely sitting on the sidelines, completely unaware that their coverage options just changed dramatically.
Read more Iraq Arrests Politicians and Officials in Corruption Sweep →
This is the kind of policy shift that can genuinely move the needle on your finances and your health. GLP-1 medications have reshaped the weight-loss conversation, and Medicare coverage makes them far more accessible for a population that carries a disproportionate burden of obesity-related conditions. The tradeable angle here is real too — watch how uptake data affects revenue expectations for Lilly and Novo going forward.
If you or someone you know is on Medicare, the move is simple: contact your plan provider directly and ask about obesity drug coverage starting July 1. Don't wait for a mailer or a TV ad that may never come. This one's on you to chase down — and the upside is worth it.
Continue reading at US Top News and Analysis
